Summary: The non-animal alternative testing market is being driven by several factors, including increasing awareness and concern over animal welfare, a growing focus on the development of non-animal ...

The core principle of BETMAT’s Kinetic Chromogenic LAL Assay is based on the specific enzymatic cascade triggered by the interaction between Limulus Amebocyte Lysate (LAL) and bacterial ...

SGS, the world’s leading testing, inspection and certification company, has expanded its analytical capabilities for the Chinese pharmaceutical industry with the introduction of nuclear magnetic ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Synthace, the leader in software and services for assay development, today announced a collaboration with Charles River Laboratories International, Inc. (Charles River), a leading global drug ...

The MarketWatch News Department was not involved in the creation of this content. Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform CAMBRIDGE, U.K.

The MarketWatch News Department was not involved in the creation of this content. New Multiplex qPCR Assay developed in collaboration with Coca-Cola Europacific Partners delivers faster, broader ...

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Germany, says it has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra™ CHO genetic ...

As a central pillar of modern society, the pharmaceutical industry bears the load of billions of lives around the world. In 2022, the global revenue of the pharmaceutical industry approximated $1.5 ...

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the ...

Merck KGaA's subsidiary MilliporeSigma has developed a first-of-its-kind “all-in-one” CHO genetic stability assay, according to an April 16 release. The company claims that the platform, called ...

(RTTNews) - Acumen Pharmaceuticals (ABOS), Monday reported that using a plasma pTau217 screening assay in its Phase?2 ALTITUDE-AD study of sabirnetug reduced trial screening costs by about 40 percent ...